AQR Capital Management
TVTX icon

AQR Capital Management’s Travere Therapeutics TVTX Stock Holding History

AQR Capital Management’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.07M Sell
305,412
-47,305
-13% -$1.41M ﹤0.01% 1387
2025
Q4 		$13.5M Buy
352,717
+39,340
+13% +$1.28M 0.01% 1083
2025
Q3 		$7.49M Buy
313,377
+85,284
+37% +$1.6M ﹤0.01% 1229
2025
Q2 		$3.38M Sell
228,093
-171,217
-43% -$2.84M ﹤0.01% 1488
2025
Q1 		$7.16M Sell
399,310
-24,714
-6% -$502K 0.01% 986
2024
Q4 		$7.39M Buy
424,024
+229,361
+118% +$4.06M 0.01% 945
2024
Q3 		$2.72M Buy
194,663
+120,594
+163% +$1.26M ﹤0.01% 1346
2024
Q2 		$609K Buy
74,069
+26,485
+56% +$178K ﹤0.01% 1969
2024
Q1 		$367K Buy
47,584
+30,401
+177% +$256K ﹤0.01% 2077
2023
Q4 		$154K Sell
17,183
-31,068
-64% -$226K ﹤0.01% 2244
2023
Q3 		$431K Buy
+48,251
New +$681K ﹤0.01% 1898
2023
Q2 		– Sell
-9,898
Closed -$223K – 2286
2023
Q1 		$223K Sell
9,898
-8,388
-46% -$178K ﹤0.01% 2021
2022
Q4 		$385K Sell
18,286
-12,691
-41% -$269K ﹤0.01% 1902
2022
Q3 		$763K Buy
30,977
+6,307
+26% +$163K ﹤0.01% 1616
2022
Q2 		$598K Sell
24,670
-38,753
-61% -$975K ﹤0.01% 1623
2022
Q1 		$1.63M Sell
63,423
-11,796
-16% -$313K ﹤0.01% 1299
2021
Q4 		$2.33M Buy
75,219
+10,457
+16% +$295K ﹤0.01% 1082
2021
Q3 		$1.57M Sell
64,762
-15,970
-20% -$293K ﹤0.01% 1301
2021
Q2 		$1.18M Buy
80,732
+34,931
+76% +$689K ﹤0.01% 1513
2021
Q1 		$1.14M Buy
45,801
+15,944
+53% +$441K ﹤0.01% 1492
2020
Q4 		$814K Buy
29,857
+3,058
+11% +$71.4K ﹤0.01% 1591
2020
Q3 		$495K Sell
26,799
-3,125
-10% -$60.7K ﹤0.01% 1735
2020
Q2 		$611K Buy
+29,924
New +$476K ﹤0.01% 1671
2019
Q3 		– Sell
-22,653
Closed -$455K – 2167
2019
Q2 		$455K Sell
22,653
-10,487
-32% -$207K ﹤0.01% 1760
2019
Q1 		$750K Sell
33,140
-3,407
-9% -$75.3K ﹤0.01% 1656
2018
Q4 		$827K Buy
36,547
+7,415
+25% +$184K ﹤0.01% 1584
2018
Q3 		$837K Buy
29,132
+15,740
+118% +$450K ﹤0.01% 1771
2018
Q2 		$365K Sell
13,392
-256
-2% -$6.82K ﹤0.01% 2075
2018
Q1 		$305K Sell
13,648
-27,158
-67% -$647K ﹤0.01% 2044
2017
Q4 		$860K Buy
40,806
+1,412
+4% +$32.3K ﹤0.01% 1726
2017
Q3 		$981K Sell
39,394
-8,151
-17% -$179K ﹤0.01% 1682
2017
Q2 		$922K Sell
47,545
-52,135
-52% -$946K ﹤0.01% 1700
2017
Q1 		$1.84M Sell
99,680
-8,255
-8% -$161K ﹤0.01% 1420
2016
Q4 		$2.04M Sell
107,935
-12,518
-10% -$256K ﹤0.01% 1392
2016
Q3 		$2.7M Buy
120,453
+33,678
+39% +$641K ﹤0.01% 1275
2016
Q2 		$1.55M Buy
86,775
+3,367
+4% +$54.5K ﹤0.01% 1431
2016
Q1 		$1.14M Sell
83,408
-20,519
-20% -$311K ﹤0.01% 1527
2015
Q4 		$2M Sell
103,927
-14,432
-12% -$288K ﹤0.01% 1238
2015
Q3 		$2.4M Sell
118,359
-25,276
-18% -$749K ﹤0.01% 1060
2015
Q2 		$4.76M Buy
143,635
+93,735
+188% +$2.57M 0.01% 850
2015
Q1 		$1.2M Buy
49,900
+9,300
+23% +$142K ﹤0.01% 1337
2014
Q4 		$497K Buy
40,600
+2,100
+5% +$21.7K ﹤0.01% 1964
2014
Q3 		$347K Buy
+38,500
New +$453K ﹤0.01% 2105

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management's TVTX Position: Q1 2026 in Review

AQR Capital Management reduced its Travere Therapeutics (TVTX) stake by 13% in Q1 2026, selling an estimated $1.41M and leaving 305,412 shares worth $9.07M. The position accounts for ﹤0.01% of the portfolio, ranked #1387.

AQR Capital Management first reported a position in TVTX in Q3 2014 and has held it in 43 quarters since. The position peaked at $13.5M in Q4 2025. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.

  • AQR Capital Management held 305,412 shares of Travere Therapeutics worth $9.07M as of Q1 2026.
  • AQR Capital Management sold 47,305 Travere Therapeutics shares in Q1 2026, an estimated $1.41M.
  • Travere Therapeutics made up ﹤0.01% of AQR Capital Management's portfolio in Q1 2026, its #1387 holding.
  • AQR Capital Management first reported a position in Travere Therapeutics in Q3 2014 and has held it in 43 quarters since.
  • AQR Capital Management's Travere Therapeutics position peaked at $13.5M in Q4 2025.
  • 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.

Based on AQR Capital Management's 13F filing for Q1 2026, filed 15 May 2026.